IRCT2016071915536N3
Completed
未知
The clinical trial of effects of nanocurcumin supplementation on blood nesfatin, insulin resistance indexes, lipids and inflammatory factors in overweight and obese patients with non-alcoholic fatty liver disease ??(NAFLD)?
Vice chancellor for research, Tehran University of Medical Sciences0 sites84 target enrollmentStarted: TBDLast updated:
Overview
- Phase
- 未知
- Status
- Completed
- Sponsor
- Vice chancellor for research, Tehran University of Medical Sciences
- Enrollment
- 84
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 25 years to 50 years (—)
- Sex
- All
Inclusion Criteria
- •Inclusion Criteria:? Non\-alcohilic fatty liver disease diagnosed by a radiologist and hepatologist using ?ultrasonography into one of three categories (mild, moderate or severe degree); Age 25–50 years; Overwight or obesity (25\=BMI\<35\).
Exclusion Criteria
- •? History of alcohol consumption at the time of the study or in the past 12 months, based on ?patient confession; Diagnosed pathological conditions affecting the liver such as viral hepatitis, acute or chronic ?liver failure, cholestasis, liver transplantation, habitual abuse of nonsteroidal anti\-inflammatory ?drugs, antibiotics, anti\-secretory drugs cause achlorhydria within 3 months before the study, ?Corticosteroids, amiodarone, valproate, prednisone, tamoxifen, perhexiline and methotrexate, ?rapid weight loss, diabetes, heart failure, thyroid disorders, kidney disease, respiratory failure, ?psychological disorders, hereditary hemochromatosis and Wilson disease, alpha\-1 antitrypsin ?deficiency, autoimmune diseases, celiac disease, use of liver fat inducer and hormonal drugs; Acute systemic disease, cystic fibrosis disease, muscular dystrophy, protein malnutrition, ?history of gastrointestinal surgery, neurological disorders, structural abnormalities of the ?gastrointestinal tract; The secondary causes of NAFLD, including drugs, surgical procedures, environmental toxins ?and total parenteral nutrition (TPN)?; Conditions lead to the physical inactivity (disability)?; Uncontrolled hypertension (\>90/140 mmHg)?; Any diagnosed malignancy; Breast\-feeding, pregnancy and or plan for pregnancy in the next 3 months; Professional athlete or regular exercise; Treatment with statins, antihypertensive and ursodeoxy colic acid, probiotics and ?multivitamin\-mineral and antioxidant supplements during the three months prior to the ?intervention; Surgery for weight loss in the last year and weight loss program for the past three month; Taking a multivitamin\-mineral and or antioxidants supplement at least once a week during the ?study; Not taking more than 10% of prescription supplements?
Investigators
Similar Trials
Completed
Phase 3
The effects of nano-curcumin on obstructive pulmonary disease patientsIRCT20191222045853N1Oroumia University of Medical Sciences60
Recruiting
Phase 3
The effect of Nanocurcumin on liver fibrosisiver fibrosis.IRCT20210427051098N2Yazd University of Medical Sciences50
Not yet recruiting
Phase 3
Investigating the effect of nanocurcumin in psychotic methamphetamine usersPsychotic methamphetamine users.???????? ????? ? ?????? ???? ?? ???? ???? ?????????F10-F19IRCT20240208060938N1Kashan University of Medical Sciences50
Completed
Phase 3
The effect of curcumin supplementation plus resistance training in treatment of patients with Parkinson'sIRCT20191231045968N1Kharazmi University40
Recruiting
Phase 3
Evaluation of The Effect of Nanocurcumin on Treatment of TinnitusIRCT20190916044785N1Hamedan University of Medical Sciences62